|Chemical and physical data|
|Molar mass||495.620 g·mol−1|
|3D model (JSmol)|
BU09059 is a potent, selective, short-acting (non-"inactivating") antagonist of the κ-opioid receptor (KOR). It was derived from the irreversible (long-acting) KOR antagonist JDTic in search of an antagonist with a reversible profile of inactivation of the KOR that could be used with less concern to treat psychiatric disorders. In addition to its reversibility, BU09059 is much more selective for the KOR than JDTic, showing 15-fold and 616-fold preference for the KOR over the μ- and δ-opioid receptors (Ki = 1.72 nM, 26.5 nM, and 1060 nM, respectively).
- Casal-Dominguez, Joseph J.; Furkert, Daniel; Ostovar, Mehrnoosh; Teintang, Linnea; Clark, Mary J.; Traynor, John R.; Husbands, Stephen. M.; Bailey, Sarah J. (March 2014). "Characterization of BU09059: A Novel Potent Selective κ-Receptor Antagonist". ACS Chemical Neuroscience. 5 (3): 177–184. doi:10.1021/cn4001507. ISSN 1948-7193. PMC 3963132. PMID 24410326.
- Urbano, Mariangela; Guerrero, Miguel; Rosen, Hugh; Roberts, Edward (May 2014). "Antagonists of the kappa opioid receptor". Bioorganic & Medicinal Chemistry Letters. 24 (9): 2021–2032. doi:10.1016/j.bmcl.2014.03.040. ISSN 0960-894X. PMID 24690494.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|